Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, explains the importance of understanding the risk of progression of smoldering myeloma to multiple myeloma to determine the best treatment strategy for each patient. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.